Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 201
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: K027992FEFDEN
Leaflet:

Download PDF Leaflet

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Keratoconjunctivitis sicca (Dry Eye) - Overview
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
Alcon Laboratories Inc
Aldeyra Therapeutics Inc
Allergan Plc
Ascendia Pharmaceuticals LLC
BioLineRx Ltd
Cambium Medical Technologies LLC
Chong Kun Dang Pharmaceutical Corp
Clementia Pharmaceuticals Inc
Dompe Farmaceutici SpA
Elasmogen Ltd
HanAll Biopharma Co Ltd
Herantis Pharma Plc
Huons Global Co Ltd
InSite Vision Inc
Kala Pharmaceuticals Inc
KPI Therapeutics Inc
Kukje Pharmaceutical Industry Co Ltd
Laboratoires Thea SA
Lipicard Technologies Ltd
Merck & Co Inc
Mitotech SA
Nanomerics Ltd
Nemus Bioscience Inc
Novaliq GmbH
Ocular Therapeutix Inc
Oculis ehf
OncoNOx ApS
Otsuka Holdings Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
Seikagaku Corp
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
TearSolutions LLC
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA
Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles
ADP-355 - Drug Profile
ADP-399 - Drug Profile
ADX-102 - Drug Profile
ADX-103 - Drug Profile
AGN-223575 - Drug Profile
AGN-232411 - Drug Profile
AL-41A1 - Drug Profile
AVA-3486 - Drug Profile
AVX-012 - Drug Profile
AX-1606 - Drug Profile
BL-1230 - Drug Profile
BRM-421 - Drug Profile
cenegermin - Drug Profile
cinhyaluronate sodium - Drug Profile
Cis-Urocanic Acid - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine SR - Drug Profile
dexamethasone acetate SR - Drug Profile
diclofenac sodium - Drug Profile
diquafosol tetrasodium - Drug Profile
Drug for Dry Eye - Drug Profile
ECF-843 - Drug Profile
Elate Ocular - Drug Profile
ELN-22 - Drug Profile
HL-036 - Drug Profile
HU-007 - Drug Profile
hyaluronate sodium - Drug Profile
ISV-101 - Drug Profile
K-089 - Drug Profile
KeraKlear - Drug Profile
KJ-14003 - Drug Profile
KJ-16001 - Drug Profile
KPI-190 - Drug Profile
Lacripep - Drug Profile
Leukothera - Drug Profile
lifitegrast - Drug Profile
LME-636 - Drug Profile
loteprednol etabonate - Drug Profile
LT-4003 - Drug Profile
NB-2222 - Drug Profile
Nov-03 - Drug Profile
Nov-07 - Drug Profile
OC-301 - Drug Profile
OCX-071 - Drug Profile
OTX-101 - Drug Profile
OX-1001 - Drug Profile
palovarotene - Drug Profile
plastoquinone decyl triphenylphosphonium bromide - Drug Profile
PPL-003 - Drug Profile
Protearin - Drug Profile
Qi-401 - Drug Profile
rebamipide - Drug Profile
RGN-259 - Drug Profile
RP-101 - Drug Profile
SA-001 - Drug Profile
SHP-659 - Drug Profile
SJP-002 - Drug Profile
solithromycin - Drug Profile
ST-266 - Drug Profile
Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders - Drug Profile
SYL-1001 - Drug Profile
tadekinig alfa - Drug Profile
TOP-1630 - Drug Profile
XG-104 - Drug Profile
zucapsaicin - Drug Profile
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Alcon Laboratories Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Elasmogen Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sylentis SAU, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd.1), H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd.2), H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd.3), H2 2017
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Alcon Laboratories Inc
Aldeyra Therapeutics Inc
Allergan Plc
Ascendia Pharmaceuticals LLC
BioLineRx Ltd
Cambium Medical Technologies LLC
Chong Kun Dang Pharmaceutical Corp
Clementia Pharmaceuticals Inc
Dompe Farmaceutici SpA
Elasmogen Ltd
HanAll Biopharma Co Ltd
Herantis Pharma Plc
Huons Global Co Ltd
InSite Vision Inc
Kala Pharmaceuticals Inc
KPI Therapeutics Inc
Kukje Pharmaceutical Industry Co Ltd
Laboratoires Thea SA
Lipicard Technologies Ltd
Merck & Co Inc
Mitotech SA
Nanomerics Ltd
Nemus Bioscience Inc
Novaliq GmbH
Ocular Therapeutix Inc
Oculis ehf
OncoNOx ApS
Otsuka Holdings Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
Seikagaku Corp
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
TearSolutions LLC
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA
Skip to top


Xerosis (Dry Skin) - Pipeline Review, H1 2014 US$ 2,000.00 Apr, 2014 · 30 pages
Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016 US$ 2,000.00 Dec, 2016 · 97 pages
Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017 US$ 2,000.00 Jun, 2017 · 104 pages

Ask Your Question

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: